$6.10
3.33% day before yesterday
Nasdaq, Nov 07, 10:00 pm CET
ISIN
US4525253062
Symbol
ICCC

ImmuCell Corporation Stock price

$6.10
-0.35 5.43% 1M
+0.91 17.53% 6M
+0.95 18.45% YTD
+2.57 72.80% 1Y
-2.14 25.97% 3Y
+0.46 8.16% 5Y
-0.57 8.55% 10Y
+1.20 24.49% 20Y
Nasdaq, Closing price Fri, Nov 07 2025
-0.21 3.33%
ISIN
US4525253062
Symbol
ICCC
Industry

Key metrics

Basic
Market capitalization
$55.2m
Enterprise Value
$59.0m
Net debt
$3.8m
Cash
$6.0m
Shares outstanding
9.1m
Valuation (TTM | estimate)
P/E
32.1 | -
P/S
2.0 | -
EV/Sales
2.1 | -
EV/FCF
33.5
P/B
1.9
Financial Health
Equity Ratio
61.0%
Return on Equity
-7.8%
ROCE
4.1%
ROIC
4.4%
Debt/Equity
0.3
Financials (TTM | estimate)
Revenue
$28.3m | -
EBITDA
$4.4m | -
EBIT
$1.7m | -
Net Income
$1.8m | -
Free Cash Flow
$1.8m
Growth (TTM | estimate)
Revenue
21.7% | -
EBITDA
481.9% | -
EBIT
144.8% | -
Net Income
143.5% | -
Free Cash Flow
291.3%
Margin (TTM | estimate)
Gross
37.4%
EBITDA
15.7% | -
EBIT
6.1%
Net
6.2% | -
Free Cash Flow
6.2%
More
EPS
$0.2
FCF per Share
$0.2
Short interest
0.1%
Employees
72
Rev per Employee
$370.0k
Show more

Is ImmuCell Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.

ImmuCell Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a ImmuCell Corporation forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a ImmuCell Corporation forecast:

Buy
86%
Hold
14%

Financial data from ImmuCell Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
28 28
22% 22%
100%
- Direct Costs 18 18
3% 3%
63%
11 11
75% 75%
37%
- Selling and Administrative Expenses 5.66 5.66
4% 4%
20%
- Research and Development Expense 3.19 3.19
29% 29%
11%
4.43 4.43
482% 482%
16%
- Depreciation and Amortization 2.69 2.69
1% 1%
10%
EBIT (Operating Income) EBIT 1.73 1.73
145% 145%
6%
Net Profit 1.76 1.76
143% 143%
6%

In millions USD.

Don't miss a Thing! We will send you all news about ImmuCell Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ImmuCell Corporation Stock News

Neutral
GlobeNewsWire
2 days ago
PORTLAND, Maine, Nov. 06, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended September 30, 2025 after th...
Neutral
GlobeNewsWire
4 days ago
PORTLAND, Maine, Nov. 04, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced the start date of its new CEO and related board changes.
Neutral
GlobeNewsWire
about one month ago
PORTLAND, Maine, Oct. 07, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the third quarter of 2025.
More ImmuCell Corporation News

Company Profile

ImmuCell Corp. engages in the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries. Its products include first defense for scours, California mastitis test kit and purified nisin intramammary treatment for mastitis. The company was founded in 1982 and is headquartered in Portland, ME.

Head office United States
CEO Michael Brigham
Employees 72
Founded 1982
Website immucell.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today